Pfizer withdraws sickle cell disease treatment on risk of …
WEB4 days ago — Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. It reported $328 million in revenues from the therapy for the full year 2023.
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB4 days ago — NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
FDA is alerting patients and health care professionals about the ...
WEB3 days ago — Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
Pfizer decision to withdrawal sickle cell drug leaves patients
WEB3 days ago — Sept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB4 days ago — Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB4 days ago — Sept. 25, 2024. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB3 days ago — Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer voluntarily withdraws all lots of sickle cell disease treatment ...
WEBWalton Oaks, 25th September 2024 - Pfizer Inc announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB4 days ago — The drug was the centerpiece in Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics in 2022 during a post-COVID M&A spree for the drugmaker. At that time, Pfizer said Oxbryta and GBT ...
Pfizer to pull sickle cell drug from market, shut down trials
WEB3 days ago — Dive Brief: Pfizer is pulling the sickle cell disease drug Oxbryta off the market and ending clinical trials of the medicine around the world due to safety concerns. Clinical data “now indicates that the overall benefit of Oxbryta no longer outweighs the risk,” Pfizer said Wednesday. The company said data show an imbalance of deaths and ...
- Some results have been removed
Skip to content